Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF | V.TLT.W

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > BTD application

<< Previous

Bullboard Posts

Next >>

Comment by enriquesuaveon Nov 29, 2022 7:02pm

188 Views

Post# 35138198

RE:RE:RE:BTD application

The FDA will look at all data and take into account increasing CR as the initial 12 patients have less of an effect on numbers the more we treat. Awesome numbers IMHO

Eoganacht wrote: I think they're great. If the 3 partial responders at 450 days are reclassified CR that will be a 450 day CR rate of 38% - double that of Keytruda which received FDA approval.

Legit62 wrote: Eoganacht, whats your feeling on these results? BTD??